echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The net profit is expected to be more than 500 million. Who can squeeze into the "1 billion army"

    The net profit is expected to be more than 500 million. Who can squeeze into the "1 billion army"

    • Last Update: 2017-06-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [China Pharmaceutical network industry trends] among the A-share listed pharmaceutical companies that have announced the performance forecast for the first half of the year, those with a net profit of more than 1 billion yuan last year are xinlitai, Shanghai Laishi and XinHeCheng In the first half of 2017, these three pharmaceutical companies are expected to have a net profit of more than 500 million yuan, with the overall performance rising In addition, the first half net profit growth of eight enterprises is expected to exceed 100% (net profit is expected to exceed 503 pharmaceutical companies who can squeeze into the "1 billion army" picture source: Baidu picture) the end of June means that 2017 will be more than half As of June 19, more than 60 A-share listed pharmaceutical companies have published the first half performance forecast, of which 44 are expected to increase, accounting for nearly 67% Three of the six pharmaceutical companies with a net profit of more than 500 million yuan are new faces Can they be included in the "one billion yuan army" this year? Why did Zixin pharmaceutical increase its net profit by more than 400% in the first half of 2017? Why did Shuangcheng pharmaceutical lose money? All the mysteries have been solved now Three "new faces", who can squeeze into the "1 billion corps" of listed A-share pharmaceutical companies that have announced the performance forecast in the first half of the year? Last year, the three pharmaceutical companies with net profits of more than 1 billion yuan are xinlitai, Shanghai Laishi and XinHeCheng In the first half of 2017, the three pharmaceutical companies are expected to have net profits of more than 500 million yuan, with the overall performance rising Hualan biological's net profit in 2016 was 780 million yuan In the first half of 2017, the net profit is expected to be between 490 million yuan and 550 million yuan, with a change range of 20% - 35% The company said in its first quarter report that the main reason for the increase was the increase in sales revenue of its blood products In addition, on April 7 of this year, the wholly-owned subsidiary Hualan bioengineering Chongqing Co., Ltd received the production approval documents of human immunoglobulin issued by CFDA, with the specifications of 150mg / bottle (10% 1.5ml) and 300mg / bottle (10% 3ml), and the drug approval numbers of gjzz s20170001 and gjzz s20170002, which is expected to further improve the company's overall performance Ruikang pharmaceutical's net profit in 2016 was 591 million yuan In the first half of 2017, the net profit is expected to be between 450 million yuan and 550 million yuan, with a change range of 105% - 155% According to the company's first quarter report, the large increase in net profit is mainly due to the increase in revenue and the implementation of the new bad debt policy In 2016, Yifan pharmaceutical made a net profit of RMB 705 million In the first half of 2017, the net profit is expected to be between 420 million yuan and 530 million yuan, with a change range of 15% - 45% According to the company's first quarter report, the main reason for the increase in performance is that the prices of vitamin B5 and other products have increased significantly compared with the same period last year The company is the world's largest production and supplier of vitamin B5 and original B5, and Yifan pharmaceutical will continue to benefit as the market situation of the products is getting better In the first half of 2017, the net profit of eight enterprises is expected to increase by more than 100%, with a large increase of 435.63% - 484.33%, and the net profit is expected to be between 110 million yuan and 120 million yuan There are three main reasons for the growth of 2017's semi annual performance: first, the sales revenue of prescription drugs keeps stable increase; second, the sales revenue of OTC drugs increases greatly; third, the sales volume of ginseng products is expected to increase substantially However, the company also mentioned that there are still uncertain factors in the sales of ginseng products in 2017 Once the expected sales revenue of ginseng products is not realized, it will have a significant impact on the company's business performance in 2017 The company's ginseng products are divided into rough processing products and deep processing products The rough processing products include white ginseng, red ginseng, raw ginseng and other series products; Deep processing products include ginseng double ear beverage, ginseng fruit and vegetable fermented beverage, fresh ginseng honey slice, yuhongyan red ginseng gelatin cake, molded red ginseng, ginseng stem and leaf extract, ginseng extract and red ginseng red date solid beverage, etc the company has obtained four series of ginseng food production licenses, involving products including beverages, candy products, preserves, tea products and substitute tea, etc According to the 2016 annual report, the gross profit margin of the company's ginseng products is as high as 76.37% Changjiang Runfa announced on May 27 this year that in view of the completion of the company's major asset restructuring of issuing shares, paying cash to purchase assets, raising supporting funds and related party transactions, the new shares have been listed on November 18, 2016 At present, the company's main business covers the original elevator guide rail industry and new pharmaceutical manufacturing business, and the company was renamed "Changjiang" Runfa Pharmaceutical Co., Ltd The net profit of the company is expected to be 140 million to 170 million yuan in the first half of the year, with an increase of 105.27% - 149.26% According to the first quarter report, the company retroactively adjusted its financial statements due to the business combination under the same control in 2016, and the company's profitability has been greatly improved due to the increase of the scope of the combination In the first half of 2017, the net profit of the three companies is expected to be 10.1975 million yuan in 2014, 151 million yuan in 2015, 14.5 million yuan in 2016 and 40-60 million yuan in the first half of 2017 According to the company's first quarter report, the reason for the performance loss is that the company continues to accelerate the strategy of "entering the field of mobile medical and health big data with wearable devices and intelligent hardware as the entrance, and then establishing a health ecosystem around users", and actively chooses to transform from a traditional OEM enterprise to a health management based on mobile Internet, with short-term marketing investment and management The management cost (including R & D investment) is relatively large, and it will take a while for the initial investment to be converted into corresponding profits Shuangcheng pharmaceutical industry started to lose net profit in the first quarter of last year, with a loss of 388 million yuan in 2016 and an expected loss of 14-16 million yuan in the first half of 2017 Shuangcheng pharmaceutical said that the sales situation of the company improved in the half year, and the loss margin narrowed compared with the same period, but it still failed to meet the expectations of the management The main reason is that the policy of the pharmaceutical industry and the influence of local bidding, the market development cost increased significantly, and the gross profit of product sales did not cover the increased cost In 2015, Watson biology lost 841 million yuan in net profit, and in 2016, its net profit recovered to 70.46 million yuan In the first half of 2017, it is estimated that it may lose money According to the strategic plan of project research and development, in the first half of 2017, the company will focus on its advantageous resources and actively promote the clinical research and project industrialization construction of key products such as 13 valent pneumococcal polysaccharide combined vaccine, recombinant human papillomavirus bivalent (16 / 18 type) vaccine (yeast), monoclonal antibody drugs, etc The research and development of biopharmaceutical projects with rich reserves of the company has the characteristics of high investment and long cycle, which may lead to a loss of accumulated net profit in the first half of the year Source: Performance Forecast of listed companies
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.